Divi’s Labs: Strong Half-Yearly Performance; More Capex Amid Better Visibility, Says ICICI Direct
Tablets fall from a machine during production. (Photographer: Andrey Rudakov/Bloomberg)

Divi’s Labs: Strong Half-Yearly Performance; More Capex Amid Better Visibility, Says ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI DIrect Report

Divi’s Laboratories Ltd.’s revenues grew 33.4% YoY to Rs 3480 crore in H1 FY21.

Generic segment grew 38.6% YoY to Rs 1777 crore. Custom synthesis grew 31.8% YoY to Rs 1409 crore. Carotenoids grew 14.0% YoY to Rs 294 crore.

Ebitda margins expanded 777 basis points YoY to 41.4% due to significantly better gross margin performance and lower other expenditure.

Subsequently, Ebitda grew 64.2% YoY to Rs 1441 crore. Net profit grew 60.8% YoY to Rs 1012 crore inline with a strong operational performance.

Click on the attachment to read the full report:

ICICI Direct Divis Lab Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.